IN2013MN00758A - - Google Patents

Download PDF

Info

Publication number
IN2013MN00758A
IN2013MN00758A IN758MUN2013A IN2013MN00758A IN 2013MN00758 A IN2013MN00758 A IN 2013MN00758A IN 758MUN2013 A IN758MUN2013 A IN 758MUN2013A IN 2013MN00758 A IN2013MN00758 A IN 2013MN00758A
Authority
IN
India
Prior art keywords
therapeutic agent
devices
implants
antibodies
months
Prior art date
Application number
Other languages
English (en)
Inventor
Paul Ashton
Leigh T Canham
Christian Barnett
Original Assignee
Psivida Inc
Psimedica Ltd
Psivida Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Psivida Inc, Psimedica Ltd, Psivida Corp filed Critical Psivida Inc
Publication of IN2013MN00758A publication Critical patent/IN2013MN00758A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/025—Other specific inorganic materials not covered by A61L27/04 - A61L27/12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/56—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2400/00—Materials characterised by their function or physical properties
    • A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01017—Lysozyme (3.2.1.17)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Biomedical Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IN758MUN2013 2010-11-01 2011-11-01 IN2013MN00758A (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40893410P 2010-11-01 2010-11-01
US201161470299P 2011-03-31 2011-03-31
PCT/US2011/058774 WO2012061377A1 (en) 2010-11-01 2011-11-01 Bioerodible silicon-based devices for delivery of therapeutic agents

Publications (1)

Publication Number Publication Date
IN2013MN00758A true IN2013MN00758A (de) 2015-06-12

Family

ID=46024803

Family Applications (1)

Application Number Title Priority Date Filing Date
IN758MUN2013 IN2013MN00758A (de) 2010-11-01 2011-11-01

Country Status (11)

Country Link
US (3) US9333173B2 (de)
EP (1) EP2635255B1 (de)
JP (2) JP6026424B2 (de)
CN (4) CN104622790A (de)
AU (2) AU2011323524B2 (de)
CA (1) CA2816576C (de)
HK (3) HK1210048A1 (de)
IN (1) IN2013MN00758A (de)
RU (1) RU2640918C2 (de)
TW (1) TWI615150B (de)
WO (1) WO2012061377A1 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9808052D0 (en) 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
AU2010246067B2 (en) 2009-05-04 2016-07-07 Eyepoint Pharmaceuticals Us, Inc. Porous silicon drug-eluting particles
RU2640918C2 (ru) 2010-11-01 2018-01-12 Псивида Юэс, Инк. Биоразлагаемые устройства на основе кремния для доставки терапевтических агентов
CN105025974A (zh) * 2013-03-12 2015-11-04 普西维达公司 包含硅基载体粒子的药物递送装置
US20140271764A1 (en) * 2013-03-12 2014-09-18 Psivida Us, Inc. Bioerodible Silicon-Based Delivery Vehicles for Delivery of Therapeutic Agents
EP2968571A4 (de) * 2013-03-15 2016-09-07 Psivida Inc Biologisch abbaubare zusammensetzungen auf siliciumbasis zur abgabe therapeutischer mittel
WO2016044366A1 (en) * 2014-09-16 2016-03-24 Psivida Us, Inc. Compositions and methods for controlled release of agents
JP6883257B2 (ja) * 2017-05-16 2021-06-09 株式会社豊田中央研究所 還元反応用固体触媒
WO2019246130A1 (en) 2018-06-19 2019-12-26 Cella Therapeutics, Llc Sustained-release drug delivery systems comprising an intraocular pressure lowering agent, a cnp compound, an npr-b compound, a tie-2 agonist, or neurotrophic agent for use for treating glaucoma or ocular hypertension
JP2021531328A (ja) 2018-06-19 2021-11-18 セラ セラピューティクス エルエルシー 神経栄養剤、アポトーシスシグナリング断片化阻害剤（ＦＡＳ）もしくはＦＡＳリガンド（ＦＡＳＬ）阻害剤、腫瘍壊死因子α（ＴＮＦ−α）もしくはＴＮＦ受容体阻害剤、ミトコンドリアペプチド、オリゴヌクレオチド、ケモカイン阻害剤、またはシステイン−アスパラギン酸プロテアーゼを含む薬剤送達系
CN120795059A (zh) 2018-08-27 2025-10-17 瑞泽恩制药公司 拉曼光谱在下游纯化中的应用
MA54325A (fr) 2019-06-05 2022-05-11 Regeneron Pharma Dispositifs et procédés pour l'administration précise de doses
JP2022132196A (ja) * 2021-02-26 2022-09-07 ナノ ターゲティング アンド セラピー バイオファーマ インコーポレイテッド 薬剤を後眼部に送達するための方法およびその使用
TWI803092B (zh) * 2021-04-01 2023-05-21 逢甲大學 具負載與釋放活性成分的奈米粒子、其製造方法與眼用裝置之應用
USD1120314S1 (en) 2022-11-30 2026-03-24 Regeneron Pharmaceuticals, Inc. Dose delivery device
CN117281687A (zh) * 2023-09-22 2023-12-26 海思盖德(苏州)生物医学科技有限公司 一种眼用引流管及其制备方法与应用

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3832458A (en) 1971-12-06 1974-08-27 River C Foundation Hydrophilic silicone composition and method
US4036979A (en) 1974-01-25 1977-07-19 American Cyanamid Company Compositions containing 4,5,6,7-tetrahydrobenz[b]thien-4-yl-ureas or derivatives and methods of enhancing growth rate
US3919723A (en) 1974-05-20 1975-11-18 Friedrichsfeld Gmbh Bone shaft or bone joint prosthesis and process
US3919060A (en) 1974-06-14 1975-11-11 Ibm Method of fabricating semiconductor device embodying dielectric isolation
DE3214667C2 (de) 1982-04-21 1985-07-18 Akzo Gmbh, 5600 Wuppertal Zusammengesetzter Körper für die Langzeitabgabe von Wirkstoffen
JPS59101145A (ja) 1982-11-30 1984-06-11 日本特殊陶業株式会社 薬液含浸多孔質セラミツクス
JPS59131346A (ja) 1983-01-17 1984-07-28 日本特殊陶業株式会社 薬液含浸多孔質セラミツクスの製造法
DE3423667A1 (de) 1984-05-08 1985-11-28 Rüdiger Dipl.-Ing. 5204 Lohmar Scheunemann Implantat fuer knochen- und zahnwurzelersatz mit spezieller uebergangsstruktur zwischen knochen und implantatkern und knochenseitig ganz oder teilweise resorbierbarer matrix
GB8422876D0 (en) 1984-09-11 1984-10-17 Secr Defence Silicon implant devices
US4608048A (en) 1984-12-06 1986-08-26 Alza Corporation Dispensing device with drug delivery patterns
US5057082A (en) 1988-11-04 1991-10-15 Plastic Injectors, Inc. Trocar assembly
ATE90203T1 (de) 1989-03-17 1993-06-15 Pitman Moore Inc Kontrollierte, verzoegerte wirkstofffreisetzung von makromolekularen proteinen.
US5167625A (en) 1990-10-09 1992-12-01 Sarcos Group Multiple vesicle implantable drug delivery system
IL105396A (en) * 1992-04-30 1998-02-22 Takeda Chemical Industries Ltd Prefilled syringe
US5366454A (en) 1993-03-17 1994-11-22 La Corporation De L'ecole Polytechnique Implantable medication dispensing device
US5370630A (en) 1993-11-12 1994-12-06 Smidebush; Michael J. Device for injection of fluidic materials into body tissue
US5489266A (en) * 1994-01-25 1996-02-06 Becton, Dickinson And Company Syringe assembly and method for lyophilizing and reconstituting injectable medication
US5558071A (en) 1994-03-07 1996-09-24 Combustion Electromagnetics, Inc. Ignition system power converter and controller
US5591453A (en) 1994-07-27 1997-01-07 The Trustees Of The University Of Pennsylvania Incorporation of biologically active molecules into bioactive glasses
US5817327A (en) 1994-07-27 1998-10-06 The Trustees Of The University Of Pennsylvania Incorporation of biologically active molecules into bioactive glasses
US5665114A (en) 1994-08-12 1997-09-09 Meadox Medicals, Inc. Tubular expanded polytetrafluoroethylene implantable prostheses
US5792099A (en) 1995-02-14 1998-08-11 Decamp; Dennis Syringe and cannula for insertion of viscoelastic material into an eye and method of using same
WO1996031197A1 (en) 1995-04-03 1996-10-10 Abbott Laboratories Homogeneous mixtures of low temperature-melting drugs and additives for controlled release
US6096344A (en) 1995-07-28 2000-08-01 Advanced Polymer Systems, Inc. Bioerodible porous compositions
GB9611437D0 (en) 1995-08-03 1996-08-07 Secr Defence Biomaterial
US5665428A (en) 1995-10-25 1997-09-09 Macromed, Inc. Preparation of peptide containing biodegradable microspheres by melt process
DE19608423A1 (de) 1996-03-05 1997-09-11 Merck Patent Gmbh Implantate mit phasenweiser Arzneistoffabgabe
FR2749169B1 (fr) * 1996-06-04 1998-08-21 Delab Procede pour constituer une preparation injectable et dispositif pour la mise en oeuvre de ce procede
US5797898A (en) 1996-07-02 1998-08-25 Massachusetts Institute Of Technology Microchip drug delivery devices
US7070590B1 (en) 1996-07-02 2006-07-04 Massachusetts Institute Of Technology Microchip drug delivery devices
US5922299A (en) 1996-11-26 1999-07-13 Battelle Memorial Institute Mesoporous-silica films, fibers, and powders by evaporation
JP3217286B2 (ja) * 1996-12-19 2001-10-09 科学技術振興事業団 Ｄｎａ固定化複合体
US6696258B1 (en) 1998-01-20 2004-02-24 Drexel University Mesoporous materials and methods of making the same
WO1999036357A1 (en) 1998-01-20 1999-07-22 Drexel University Mesoporous materials and methods of making the same
US6060036A (en) 1998-02-09 2000-05-09 Implant Sciences Corporation Radioactive seed implants
GB9808052D0 (en) * 1998-04-17 1998-06-17 Secr Defence Implants for administering substances and methods of producing implants
GB9815819D0 (en) 1998-07-22 1998-09-16 Secr Defence Transferring materials into cells and a microneedle array
EP1140027B1 (de) 1998-12-23 2005-10-12 Alza Corporation Dosierungsformen, die poröse partikel enthalten
EP1154691A4 (de) * 1999-01-05 2004-07-07 Massachusetts Eye & Ear Infirm Gezielte transsklerale gesteuerte wirkstoffabgabe an die retina und choroidae
AU7881000A (en) * 1999-08-16 2001-03-13 Henceforth Hibernia, Inc. Therapeutic and prophylactic compositions including catalytic biomimetic solids and methods to prepare and use them
GB9924334D0 (en) 1999-10-15 1999-12-15 Secr Defence Pharmaceutical products and methods of fabrication therefor
IL149004A0 (en) * 1999-10-18 2002-11-10 Ferx Inc Magnetic targeted carrier composed of iron and porous materials for the targeted delivery of biologically active agents
SE9903958D0 (sv) 1999-11-02 1999-11-02 Boerje Sellergren Porous materials for selective binding or transport of molecular guests
US6521284B1 (en) 1999-11-03 2003-02-18 Scimed Life Systems, Inc. Process for impregnating a porous material with a cross-linkable composition
AUPQ573300A0 (en) 2000-02-21 2000-03-16 Australian Nuclear Science & Technology Organisation Controlled release ceramic particles, compositions thereof, processes of preparation and methods of use
KR100717916B1 (ko) 2000-02-28 2007-05-11 아방티 파르마 소시에테 아노님 캄프토테신 및 피리미딘 유도체를 포함하는 암 치료용 조성물
IL134830A0 (en) 2000-03-01 2001-05-20 Chay 13 Medical Res Group N V Peptides and immunostimulatory and anti-bacterial pharmaceutical compositions containing them
JP2003526671A (ja) 2000-03-14 2003-09-09 レストラゲン，インコーポレイテッド 幽門洞−十二指腸運動性に対するグルカゴン様ペプチド‐１（７−３６）の作用
GB0008494D0 (en) * 2000-04-07 2000-05-24 Secr Defence Microprojectile delivery system
GB2365769A (en) 2000-08-18 2002-02-27 Secr Defence Skin preparations containing silicon
GB0104383D0 (en) 2001-02-22 2001-04-11 Psimedica Ltd Cancer Treatment
US6973718B2 (en) 2001-05-30 2005-12-13 Microchips, Inc. Methods for conformal coating and sealing microchip reservoir devices
EP1542926A1 (de) 2002-08-23 2005-06-22 McMaster University Verfahren und verbindungen zur steuerung der morphologie und des schrumpfs von siliciumdioxid, das sich von polyolmodifizierten silanen ableitet
AU2003272575B2 (en) 2002-09-18 2007-11-08 Allergan, Inc. Methods and apparatus for delivery of ocular implants
US7713778B2 (en) 2003-02-13 2010-05-11 Univ California Nanostructured casting of organic and bio-polymers in porous silicon templates
US7433811B2 (en) 2003-05-06 2008-10-07 The Regents Of The University Of California Direct patterning of silicon by photoelectrochemical etching
US7563451B2 (en) 2003-07-22 2009-07-21 Iowa State University Research Foundation, Inc. Capped mesoporous silicates
WO2005041936A2 (en) 2003-10-21 2005-05-12 Psimedica Limited Methods of treatment of cancer using a composition comprising a cytotoxic drug and a porous carrier material
GB0324483D0 (en) * 2003-10-21 2003-11-19 Psi Medica Ltd Composite material
US20050181049A1 (en) 2003-11-19 2005-08-18 Dong Liang C. Composition and method for enhancing bioavailability
MX2007003280A (es) 2004-09-17 2007-05-24 Ormco Corp Aparato de tratamiento medico y metodo de manufactura de aguja.
US20060067979A1 (en) 2004-09-30 2006-03-30 Bausch & Lomb Incorporated Ophthalmic drug release device for multiple drug release
WO2006037160A1 (en) * 2004-10-05 2006-04-13 The University Of Melbourne Porous polyelectrolyte materials
EP3381446A1 (de) 2004-10-29 2018-10-03 The Regents of The University of California Poröse photonische kristalle zur verabreichung von wirkstoffen ins auge
JP4977475B2 (ja) 2004-12-21 2012-07-18 日本電気株式会社 フィルム外装電気デバイス用ケース
JP2007091716A (ja) 2005-08-29 2007-04-12 Kuraray Co Ltd 水中薬剤徐放性微粒子及びその製造方法
GB0526332D0 (en) 2005-12-23 2006-02-01 Psimedica Ltd Pharmaceutical product
WO2007106868A2 (en) * 2006-03-14 2007-09-20 University Of Rochester Cell culture devices having ultrathin porous membrane and uses thereof
EP2004172B1 (de) 2006-03-31 2019-03-13 Mati Therapeutics Inc. Wirkstofffreisetzungsstrukturen und zusammensetzungen für nasolacrimales system
JP4984644B2 (ja) * 2006-05-19 2012-07-25 株式会社ジェイ・エム・エス 注射装置
US20080057102A1 (en) 2006-08-21 2008-03-06 Wouter Roorda Methods of manufacturing medical devices for controlled drug release
KR101329658B1 (ko) 2006-09-25 2013-11-14 아처 다니엘 미드랜드 캄파니 초흡수성 표면처리된 카르복시알킬화 다당류 및 그 제조방법
JP5141948B2 (ja) * 2007-07-09 2013-02-13 株式会社豊田中央研究所 バイモダルな細孔構造を有する球状シリカ系メソ多孔体及びその製造方法
KR20100047258A (ko) * 2007-07-10 2010-05-07 더 리전트 오브 더 유니버시티 오브 캘리포니아 선택된 조직에 조성물을 전달하는 물질 및 방법
US20130084243A1 (en) 2010-01-27 2013-04-04 Liliane Goetsch Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
WO2010036702A1 (en) 2008-09-25 2010-04-01 Cephalon, Inc. Liquid formulations of bendamustine
GB0817936D0 (en) * 2008-09-30 2008-11-05 Intrinsiq Materials Global Ltd Porous materials
GB0817938D0 (en) * 2008-09-30 2008-11-05 Intrinsiq Materials Global Ltd Cosmetic formulations
JP5369725B2 (ja) 2009-01-30 2013-12-18 株式会社ニコン 撮像装置
SG173455A1 (en) 2009-02-04 2011-09-29 Agency Science Tech & Res Hollow silica particle with a polymer thereon
US20110300222A1 (en) 2009-02-20 2011-12-08 The Regents Of The University Of California Luminescent porous silicon nanoparticles, methods of making and using same
WO2010111627A1 (en) 2009-03-26 2010-09-30 Psivida Us, Inc. Implantable formulations of bisphosphonic acids
JP5382700B2 (ja) 2009-03-27 2014-01-08 独立行政法人産業技術総合研究所 ロッド状多孔質シリカ粒子
AU2010246067B2 (en) 2009-05-04 2016-07-07 Eyepoint Pharmaceuticals Us, Inc. Porous silicon drug-eluting particles
US20110028412A1 (en) 2009-08-03 2011-02-03 Cappellos, Inc. Herbal enhanced analgesic formulations
DE102010008982A1 (de) 2010-02-24 2011-08-25 Bayer Innovation GmbH, 40225 Siliciumhaltiges, biologisch degradierbares Material zur anti-inflammatorischen Therapie
GB201017048D0 (en) 2010-10-08 2010-11-24 Ucl Business Plc Composition
RU2640918C2 (ru) 2010-11-01 2018-01-12 Псивида Юэс, Инк. Биоразлагаемые устройства на основе кремния для доставки терапевтических агентов
US20120238994A1 (en) 2010-12-22 2012-09-20 Martin Nazzaro Two-piece injectable drug delivery device with heat-cured seal
US20120207682A1 (en) 2011-02-11 2012-08-16 Psivida Us, Inc. Methods of treating macular edema using antiedema therapeutics
US20140065221A1 (en) 2011-03-31 2014-03-06 Galderma Research & Development Compositions comprising a filler product and at least one bioresorbable and biodegradable silica-based material
ES2727203T3 (es) 2011-08-29 2019-10-14 Mati Therapeutics Inc Administración por liberación sostenida de agentes activos para tratar glaucoma e hipertensión ocular
KR20150085078A (ko) 2012-11-21 2015-07-22 아지오스 파마슈티컬스 아이엔씨. 글루타마제 억제제 및 사용 방법
US20140271764A1 (en) 2013-03-12 2014-09-18 Psivida Us, Inc. Bioerodible Silicon-Based Delivery Vehicles for Delivery of Therapeutic Agents
WO2016077632A2 (en) 2014-11-13 2016-05-19 Buck Institute For Research On Aging Inhibition of proline catabolism for the treatment of cancer and other therapeutic applications

Also Published As

Publication number Publication date
US20160243276A1 (en) 2016-08-25
HK1210415A1 (en) 2016-04-22
RU2640918C2 (ru) 2018-01-12
CN104622789A (zh) 2015-05-20
US20170035690A1 (en) 2017-02-09
AU2016259330B2 (en) 2018-11-08
JP2013541562A (ja) 2013-11-14
JP6026424B2 (ja) 2016-11-16
CA2816576C (en) 2020-06-02
AU2011323524A1 (en) 2013-05-23
CN103282020A (zh) 2013-09-04
AU2016259330A1 (en) 2016-12-08
EP2635255A4 (de) 2016-11-09
CN104622790A (zh) 2015-05-20
TW201306867A (zh) 2013-02-16
AU2011323524B2 (en) 2016-12-08
US9333173B2 (en) 2016-05-10
WO2012061377A1 (en) 2012-05-10
HK1210048A1 (en) 2016-04-15
EP2635255A1 (de) 2013-09-11
EP2635255B1 (de) 2019-08-21
CA2816576A1 (en) 2012-05-10
HK1210416A1 (en) 2016-04-22
CN104586742A (zh) 2015-05-06
TWI615150B (zh) 2018-02-21
JP6189460B2 (ja) 2017-08-30
RU2013119438A (ru) 2014-12-10
US11026885B2 (en) 2021-06-08
US20120177695A1 (en) 2012-07-12
US9808421B2 (en) 2017-11-07
JP2016121173A (ja) 2016-07-07
CN103282020B (zh) 2016-10-26

Similar Documents

Publication Publication Date Title
GB2465677B (en) Non-systemic delivery of satiogens for use in the treatment of obesity and/or diabetes
EP4461326A3 (de) Flexibles system zur freisetzung eines ankers
GB2471588A (en) Therapeutic peptidomimetic macrocycles
NZ707377A (en) Combination therapy methods for treating proliferative diseases
CY1119192T1 (el) Μεθοδος κρυσταλλωσης και βιοδιαθεσιμοτητα
MX2019003173A (es) Terapia de combinacion con agonistas de peptido natriuretico tipo c (cnp) de liberacion controlada.
EP3192526A3 (de) Exosomen zur freisetzung von biotherapeutika
IL211952A0 (en) Implantable device for the delivery of risperidone and methods of use thereof
MX339125B (es) Endoprotesis de metal desnudo con receptaculos eluyentes de farmacos.
UA108885C2 (uk) Композиція рисперидону для ін'єкційної депо-форми
NZ606825A (en) Methods and compositions for treating complement-associated disorders
GB2458229B (en) Magnetic carrier and medical prepartion for controllable delivery and release of active substances
MX337614B (es) Tratamiento de lupus nefritis usando laquinimod.
EP2300035A4 (de) Gemischte agonisten auf gip-basis zur behandlung von stoffwechselerkrankungen und fettsucht
PL2210588T3 (pl) Kompozycje pianotwórcze do leczenia skóry ludzkiej zasadniczo niezawierające aktywnych składników farmaceutycznych
BR112013000841A2 (pt) composições farmacêuticas, métodos de tratamento da obesidade e distúrbios metabólicos relacionados, de redução da massa corpórea de mamífero, do crescimento da massa corpórea de mamífero, do consumo de comida em mamífero, de trtamento de paciente de adicção de substância psicoativa, de adicção de substância psicoativa e uso de forma ativada-potencializada de anticorpo para receptor de canabinoide humano.
WO2012037519A3 (en) Acceleration of wound healing by growth hormone releasing hormone and its agonists
MX2012014521A (es) Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado comun e inflamacion.
MX340636B (es) Dispositivo oftalmico que tiene capacidad de liberacion de agentes terapeuticos y metodos para formar el mismo.
IL210545A (en) Transplantation devices for use of octreotide transport and use of octreotide to create drugs
ZA201403596B (en) Composition for use in the promotion of healthy bone growth and/or in the prevention and/or treatment of bone disease
MX2009006327A (es) Compuestos heterociclicos y metodos de uso de los mismos.
EP2866795A4 (de) Polyenolzinkbindemittel zur aktiven förderung der inaktivierung von krebsstammzellen und zur potenzierung zytotoxischer antitumorwirkstoffe
IL211953A0 (en) Implantable device for the delivery of octreotide and methods of use thereof
MX367070B (es) Sistemas de administracion de farmaco y metodos para el tratamiento de la prostata.